A Phase 4, Randomized, Open-Label, Three-Arm Study to Evaluate Impleme
Research payments
$816,777
Through program year 2025, $816,777 in research payments was reported against A Phase 4, Randomized, Open-Label, Three-Arm Study to Evaluate Impleme, across 316 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $139,120 | 85 |
| 2024 | Research | $456,880 | 157 |
| 2023 | Research | $210,277 | 73 |
| 2022 | Research | $10,500 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jason Schneider Atlanta, GA Named on 31 payments
- Rachel Scott Washington, DC Named on 25 payments
- Ricky Hsu New York, NY Named on 22 payments
- Zandraetta Tims-Cook Atlanta, GA Named on 14 payments
- Megan Dieterich Washington, DC Named on 10 payments
- Steven Barnett Phoenix, AZ Named on 10 payments
- Marye Bernard Memphis, TN Named on 10 payments
- Michael Dunn Temple Terrace, FL Named on 10 payments
- Elizabeth Secord Detroit, MI Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.